Pathalys Pharma Stock
HealthTechLooking to sell Pathalys Pharma stock or options?
Pathalys Pharma develops advanced therapeutics aimed at addressing the unmet needs of managing late-stage chronic kidney diseases. The company has created upacicalcet, a novel calcimimetic designed to enhance the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. It works by mimicking calcium's effects on tissues through activating the calcium-sensing receptor found in various human organs. This innovation allows healthcare providers to better treat patients with end-stage critical kidney disease.
The Carlyle Group, Catalys Pacific, Launch Therapeutics, KB Investment, Marshall Wace, JPMorgan Life Sciences Private Capital, TCG Crossover Management, Abingworth, Japan Post Investment, DaVita Venture Group.